Curosurf 120mg injection contains active components such as Poractant alfa. It is a lung surfactant medication used to treat Respiratory Distress Syndrome (RDS) in premature infants. It is a lifesaving medication that has improved the survival and outcomes of many premature infants. It has been shown to reduce the risk of death, the need for mechanical ventilation, and the length of hospital stay in premature infants with RDS. It is a good option for infants who are at risk for developing bronchopulmonary dysplasia (BPD), a chronic lung disease that can develop in premature infants. It is more stable than other surfactant medications, which means it can be stored longer without losing effectiveness. If someone is hypersensitive to Curosurf 120mg injection, they should not receive the medication. They may experience a severe allergic reaction, such as anaphylaxis. It should not be used for infants with severe RDS. This is because the medication may not be effective in these infants. This medication should not be given to infants with a history of porcine protein hypersensitivity. This medication can increase the risk of bleeding. Therefore, it should not be given to infants with active bleeding. It may not be effective in infants with neonatal pneumonia and meconium aspiration syndrome. Curosurf 120mg injection is not used in old age because it is ineffective in adults.